	US 12,391,974 B2
	Methods of detecting alloantibodies to HLA class II antigens
Robert A. Bray, Snellville, GA (US); and Jar-How Lee, Los Angeles, CA (US)
Assigned to Emory University, Atlanta, GA (US); and One Lambda, Inc., West Hills, CA (US)
Filed by EMORY UNIVERSITY, Atlanta, GA (US); and ONE LAMBDA, INC., West Hills, CA (US)
Filed on Sep. 15, 2022, as Appl. No. 17/932,600.
Application 17/932,600 is a division of application No. 16/549,321, filed on Aug. 23, 2019, abandoned.
Claims priority of provisional application 62/722,042, filed on Aug. 23, 2018.
Prior Publication US 2023/0029386 A1, Jan. 26, 2023
Int. Cl. G01N 33/68 (2006.01); C07K 14/74 (2006.01); C12N 15/85 (2006.01); C12Q 1/68 (2018.01); G01N 33/554 (2006.01)

CPC C12Q 1/68 (2013.01) [C07K 14/70539 (2013.01); C12N 15/85 (2013.01); G01N 33/554 (2013.01); G01N 33/6854 (2013.01); C12N 2015/8518 (2013.01)]

12 Claims

1. A method of screening for antibodies that specifically bind an HLA Class II antigen in which a CLIP peptide is present in the peptide binding groove comprising the steps of:

preparing a panel comprising a solid-phase substrate having an HLA Class II antigen in which a CLIP peptide is present in the peptide binding groove immobilized or attached thereto, wherein the CLIP peptide is a subsequence of human CD74 invariant chain comprising MRMATPLLM (SEQ ID NO: 1);

obtaining a serum sample from a human subject,

contacting the panel with the serum sample, and

detecting binding of antibodies in said serum sample to the HLA Class II antigen in which a CLIP peptide is present in the peptide binding groove.